Literature DB >> 15003957

Association between initial disease presentation, lung disease outcomes, and survival in patients with cystic fibrosis.

HuiChuan J Lai1, Yu Cheng, Hyungjun Cho, Michael R Kosorok, Philip M Farrell.   

Abstract

This US study was conducted to determine whether mode of diagnosis and initial disease presentation influence lung disease and survival in patients with cystic fibrosis. The study population included 27,703 patients reported to the 1986-2000 Cystic Fibrosis Foundation Registry. Patients were segregated into four diagnostic categories: meconium ileus (MI), prenatal/neonatal screening (SCREEN), positive family history (FH), and symptoms other than meconium ileus (SYMPTOM). When compared with patients in the SCREEN group, those in the MI or SYMPTOM group were found to have significantly greater risks of shortened survival, Pseudomonas aeruginosa acquisition, and forced expiratory volume in 1 second (FEV(1)) below 70% of predicted. In the SYMPTOM group, the greatest risks of shortened survival, P. aeruginosa acquisition, and FEV(1) <70% occurred for patients presenting with combined respiratory and gastrointestinal symptoms, followed by respiratory or gastrointestinal symptoms alone; the best outcomes were in patients with other presenting features. Additionally, patients with presumably "severe" genotypes (DeltaF508 plus other class I, II, III mutations in both alleles) had greater risks of shortened survival and P. aeruginosa acquisition compared with patients with presumably "mild" genotypes (class IV or V mutations in one or both alleles).

Entities:  

Mesh:

Year:  2004        PMID: 15003957     DOI: 10.1093/aje/kwh083

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  26 in total

1.  Quantile regression for doubly censored data.

Authors:  Shuang Ji; Limin Peng; Yu Cheng; HuiChuan Lai
Journal:  Biometrics       Date:  2011-09-27       Impact factor: 2.571

2.  Growth and pulmonary outcomes during the first 2 y of life of breastfed and formula-fed infants diagnosed with cystic fibrosis through the Wisconsin Routine Newborn Screening Program.

Authors:  Sarah A Jadin; Grace S Wu; Zhumin Zhang; Suzanne M Shoff; Benjamin M Tippets; Philip M Farrell; Tami Miller; Michael J Rock; Hara Levy; HuiChuan J Lai
Journal:  Am J Clin Nutr       Date:  2011-03-23       Impact factor: 7.045

3.  Relative contribution of genetic and nongenetic modifiers to intestinal obstruction in cystic fibrosis.

Authors:  Scott M Blackman; Rebecca Deering-Brose; Rita McWilliams; Kathleen Naughton; Barbara Coleman; Teresa Lai; Marilyn Algire; Suzanne Beck; Julie Hoover-Fong; Ada Hamosh; M Daniele Fallin; Kristen West; Dan E Arking; Aravinda Chakravarti; David J Cutler; Garry R Cutting
Journal:  Gastroenterology       Date:  2006-07-24       Impact factor: 22.682

4.  Relationships among health-related quality of life, pulmonary health, and newborn screening for cystic fibrosis.

Authors:  Audrey Tluczek; Tara Becker; Anita Laxova; Adam Grieve; Caroline N Racine Gilles; Michael J Rock; William M Gershan; Christopher G Green; Philip M Farrell
Journal:  Chest       Date:  2010-11-24       Impact factor: 9.410

Review 5.  Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice.

Authors:  C Castellani; H Cuppens; M Macek; J J Cassiman; E Kerem; P Durie; E Tullis; B M Assael; C Bombieri; A Brown; T Casals; M Claustres; G R Cutting; E Dequeker; J Dodge; I Doull; P Farrell; C Ferec; E Girodon; M Johannesson; B Kerem; M Knowles; A Munck; P F Pignatti; D Radojkovic; P Rizzotti; M Schwarz; M Stuhrmann; M Tzetis; J Zielenski; J S Elborn
Journal:  J Cyst Fibros       Date:  2008-05       Impact factor: 5.482

6.  Feasibility study to inform the design of a randomised controlled trial to eradicate Pseudomonas aeruginosa infection in individuals with cystic fibrosis.

Authors:  Helen R Hickey; Ashley P Jones; Warren Lenney; Paula R Williamson; Rosalind L Smyth
Journal:  Trials       Date:  2010-02-05       Impact factor: 2.279

7.  Pulmonary outcome differences in U.S. and French cystic fibrosis cohorts diagnosed through newborn screening.

Authors:  Aimee C Walsh; Gilles Rault; Zhanhai Li; Virginie Scotet; Ingrid Duguépéroux; Claude Férec; Michel Roussey; Anita Laxova; Philip M Farrell
Journal:  J Cyst Fibros       Date:  2009-11-18       Impact factor: 5.482

8.  Cystic fibrosis: benefits and clinical outcome.

Authors:  K O McKay
Journal:  J Inherit Metab Dis       Date:  2007-07-06       Impact factor: 4.982

Review 9.  Meconium Ileus.

Authors:  John H T Waldhausen; Morgan Richards
Journal:  Clin Colon Rectal Surg       Date:  2018-02-25

10.  Health-related quality of life in children and adolescents with cystic fibrosis: convergent validity with parent-reports and objective measures of pulmonary health.

Authors:  Audrey Tluczek; Tara Becker; Adam Grieve; Anita Laxova; Michael J Rock; William M Gershan; Christopher G Green; Philip M Farrell
Journal:  J Dev Behav Pediatr       Date:  2013-05       Impact factor: 2.225

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.